文献速递类风湿关节炎

艾布替尼或乌帕替尼单用或联合(ABBV-599)治疗对生物制剂应答不足或不耐受的类风湿关节炎患者的安全性和有效性:一项多中心、双盲、随机、对照、2期试验

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.
PubMed 文献 · Lancet Rheumatol · 2022-04-27

这项多中心、双盲、随机、对照2期试验在8个欧洲和北美国家的75个社区中心纳入242例对生物制剂改善病情抗风湿药应答不足或不耐受的类风湿关节炎患者,比较ABBV-599(乌帕替尼15 mg联合艾布替尼60 mg)、艾布替尼各剂量、乌帕替尼15 mg与安慰剂的疗效和安全性。第12周DAS28-CRP较基线变化方面,ABBV-599和乌帕替尼15 mg较安慰剂显著改善,而艾布替尼单用各剂量均无显著改善。作者认为ABBV-599的疗效改善由JAK抑制剂乌帕替尼驱动,BTK抑制剂艾布替尼未见可辨别的作用。

要点

  • ABBV-599(乌帕替尼15 mg联合艾布替尼60 mg)第12周DAS28-CRP较基线变化较安慰剂显著改善。
  • 乌帕替尼15 mg单药第12周DAS28-CRP较基线变化较安慰剂显著改善。
  • 艾布替尼单用各剂量(60 mg、20 mg、5 mg)较安慰剂均无显著疗效改善。

核心结论

  • ABBV-599对类风湿关节炎疾病活动度指标的显著改善由JAK抑制剂乌帕替尼驱动,BTK抑制剂艾布替尼未见可辨别的作用。

研究设计与样本

  • 多中心、双盲、平行组、剂量探索性、随机、对照2期试验,在欧洲和北美8个国家的75个社区中心开展。
  • 纳入18岁及以上、对生物制剂改善病情抗风湿药应答不足或不耐受的类风湿关节炎患者242例。
  • 按3:2:2:2:2:1随机分配至ABBV-599(乌帕替尼15 mg联合艾布替尼60 mg,n=62)、艾布替尼60 mg(n=41)、艾布替尼20 mg(n=39)、艾布替尼5 mg(n=41)、乌帕替尼15 mg(n=40)或安慰剂(n=19),每日口服。
  • 随机化按既往生物制剂改善病情抗风湿药数量分层;研究者、研究站点人员和患者全程设盲。
  • 主要终点为所有接受研究药物的患者第12周DAS28-CRP较基线的变化;同时评估药代动力学和安全性。

主要发现

  • 与安慰剂相比,第12周DAS28-CRP较基线变化的最小二乘均值:ABBV-599为-1.44(90% CI -2.03至-0.85;p<0.0001),乌帕替尼15 mg为-1.75(90% CI -2.38至-1.13;p<0.0001)。
  • 与安慰剂相比,第12周DAS28-CRP较基线变化的最小二乘均值:艾布替尼60 mg为-0.40(90% CI -1.03至0.23;p=0.29),艾布替尼20 mg为-0.20(90% CI -0.85至0.44;p=0.61),艾布替尼5 mg为-0.21(90% CI -0.84至0.41;p=0.57)。
  • 艾布替尼单用任何剂量与安慰剂相比均未检测到疗效指标的显著改善,尽管血浆暴露充分且靶点结合。
  • 242例患者中113例(47%)观察到治疗中出现的不良事件,各组比例相似。
  • 242例患者中204例(84%)为女性、38例(16%)为男性,220例(91%)为白人;基线平均年龄58.0岁(SD 11.3)。

关键数值与推荐

  • 主要终点为第12周DAS28-CRP较基线的变化。
  • ABBV-599组第12周DAS28-CRP较基线变化的最小二乘均值为-1.44(90% CI -2.03至-0.85;p<0.0001)。
  • 乌帕替尼15 mg组第12周DAS28-CRP较基线变化的最小二乘均值为-1.75(90% CI -2.38至-1.13;p<0.0001)。
  • 艾布替尼60 mg组、20 mg组、5 mg组第12周DAS28-CRP较基线变化的最小二乘均值分别为-0.40(90% CI -1.03至0.23;p=0.29)、-0.20(90% CI -0.85至0.44;p=0.61)、-0.21(90% CI -0.84至0.41;p=0.57)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of autoimmune diseases. We aimed to determine whether ABBV-599 could increase the treatment response for patients with active rheumatoid arthritis compared with inhibiting either pathway alone, while maintaining an acceptable safety profile. METHODS: We conducted a multicentre, double-blind, parallel-group, dose-exploratory, randomised, controlled, phase 2 trial at 75 community sites in eight countries in Europe and North America. We enrolled patients who were 18 years or older with rheumatoid arthritis and inadequate response or intolerance to biological disease-modifying antirheumatic drugs. Eligible patients were randomly assigned (3:2:2:2:2:1) via interactive response technology to receive daily, orally administered ABBV-599 (ie, upadacitinib 15 mg plus elsubrutinib 60 mg), elsubrutinib 60 mg, elsubrutinib 20 mg, elsubrutinib 5 mg, upadacitinib 15 mg, or placebo. Randomisation was stratified by the number of previous biological disease-modifying antirheumatic drugs. The investigator, study site personnel, and patients were masked throughout the study. The primary endpoint was change from baseline in disease activity score of 28 joints with C-reactive protein (DAS28-CRP) at week 12 for all patients who received a study drug. Pharmacokinetics and safety were also assessed. This study is registered with ClinicalTrials.gov, number NCT03682705. FINDINGS: Between Oct 8, 2018, and March 26, 2020, 242 patients were randomly assigned to receive ABBV-599 (n=62), elsubrutinib 60 mg (n=41), elsubrutinib 20 mg (n=39), elsubrutinib 5 mg (n=41), upadacitinib 15 mg (n=40), or placebo (n=19). Of the 242 patients, 204 (84%) were female, 38 (16%) were male, and 220 (91%) were White; the mean age at baseline was 58·0 years (SD 11·3). Compared with placebo, the least squares mean changes from baseline in DAS28-CRP were -1·44 (90% CI -2·03 to -0·85; p<0·0001) for ABBV-599, -0·40 (-1·03 to 0·23; p=0·29) for elsubrutinib 60 mg, -0·20 (-0·85 to 0·44; p=0·61) for elsubrutinib 20 mg, -0·21 (-0·84 to 0·41; p=0·57) for elsubrutinib 5 mg, and -1·75 (-2·38 to -1·13; p<0·0001) for upadacitinib. No significant improvements in efficacy measures for elsubrutinib alone (any dose) versus placebo were detected, despite adequate plasma exposure and target engagement. Treatment-emergent adverse events were observed in 113 (47%) of 242 patients, with similar proportions for all groups. INTERPRETATION: Significant improvements in disease activity metrics of rheumatoid arthritis with ABBV-599 were driven by the JAK inhibitor upadacitinib with no discernible effect by the BTK inhibitor elsubrutinib. FUNDING: AbbVie.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Friedman A, Drescher E, et al. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. Lancet Rheumatol. 2022. PMID: 38293957. doi:10.1016/S2665-9913(22)00092-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。